60 related articles for article (PubMed ID: 1700002)
1. Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region.
Masuda T; Matsushita S; Kuroda MJ; Kannagi M; Takatsuki K; Harada S
J Immunol; 1990 Nov; 145(10):3240-6. PubMed ID: 1700002
[TBL] [Abstract][Full Text] [Related]
2. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
3. Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1.
Laisney IL; Benjamin H; Gefter M; Strosberg AD
Eur J Immunol; 1996 Jul; 26(7):1634-40. PubMed ID: 8766572
[TBL] [Abstract][Full Text] [Related]
4. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
[TBL] [Abstract][Full Text] [Related]
5. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
6. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
7. Antigenic variation of SIV: mutations in V4 alter the neutralization profile.
Kinsey NE; Anderson MG; Unangst TJ; Joag SV; Narayan O; Zink MC; Clements JE
Virology; 1996 Jul; 221(1):14-21. PubMed ID: 8661410
[TBL] [Abstract][Full Text] [Related]
8. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
Gorny MK; Xu JY; Karwowska S; Buchbinder A; Zolla-Pazner S
J Immunol; 1993 Jan; 150(2):635-43. PubMed ID: 7678279
[TBL] [Abstract][Full Text] [Related]
9. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
10. Genotypic and phenotypic characterization of a neutralization-resistant breakthrough population of HIV-1.
Sirko DA; Ehrlich GD
Virology; 1996 Apr; 218(1):238-42. PubMed ID: 8615028
[TBL] [Abstract][Full Text] [Related]
11. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
12. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
Kang CY; Hariharan K; Posner MR; Nara P
J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
[TBL] [Abstract][Full Text] [Related]
13. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
[TBL] [Abstract][Full Text] [Related]
14. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
[TBL] [Abstract][Full Text] [Related]
15. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
Hiramatsu K; Tadano M; Men R; Lai CJ
Virology; 1996 Oct; 224(2):437-45. PubMed ID: 8874504
[TBL] [Abstract][Full Text] [Related]
17. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.
Jagodzinski PP; Wustner J; Kmieciak D; Wasik TJ; Fertala A; Sieron AL; Takahashi M; Tsuji T; Mimura T; Fung MS; Gorny MK; Kloczewiak M; Kaneko Y; Kozbor D
Virology; 1996 Dec; 226(2):217-27. PubMed ID: 8955041
[TBL] [Abstract][Full Text] [Related]
18. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
[TBL] [Abstract][Full Text] [Related]
19. Distribution of linear antigenic epitopes on GP120 encoded in sibling clones of novel New York HIV-1 subtype B isolates.
Riley JP; Pestano GA; Harewood K; Alfred LJ; Guyden J; Boto WM
Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S83-91. PubMed ID: 8574151
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the HIV type 1 V3 loop under selection pressure with neutralizing monoclonal antibody NM-01.
Yoshida K; Nakamura M; Ohno T
AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1283-90. PubMed ID: 9339845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
